Alternatively, IGF1R inhibition may increase the sensitivity of HCC tumors to other compounds and several additional phase II trials are in their early stages investigating the effects of IGF1R-targeted treatments in combination with sorafenib, regorafenib or erlotinib. This evidence concerns the gene IGF1R and hepatocellular carcinoma.